Compare Gilead Sciences, Inc. (GILD) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Royal Caribbean Cruises Ltd — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $168.35B), while Royal Caribbean Cruises Ltd trades at $306.37 (market cap $82.15B). The key difference: Gilead Sciences, Inc. is far larger — about 2× Royal Caribbean Cruises Ltd's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | RCL | |
|---|---|---|
Market Cap | $168.35B | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $365.84 |
52-Week Low | $110.56 | $246.71 |
Enterprise Value | $191.42B | $104.79B |
Dividend Yield | 2.42% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Royal Caribbean (RCL) trades at $308, down 3.75% today, as strong earnings growth and bullish technical signals are tempered by geopolitical concerns affecting European demand. The company reported Q2 2026 EPS of $4.21, beating estimates, and raised full-year guidance, with revenue reaching $17.93B in 2025. Technical analysis shows a bullish trend with support at $305 and resistance at $314, while fundamentals highlight robust profitability with a 23.54% net margin and 45.33% ROE.
RCL presents a compelling growth story with record bookings and fleet expansion through 2028, though risks include high debt levels, capital-intensive spending, and geopolitical volatility. Analyst consensus is bullish with a $343 price target, but investors should weigh strong cash flow generation against ongoing investment requirements and market sensitivity to economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
